Please login to the form below

Not currently logged in
Email:
Password:

Pfizer agrees MoU with Chinese firm

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co that includes selling and distributing an unnamed Pfizer product in China. 

The companies plan to explore future co-operation opportunities, including further distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities. 

The companies also expect to strengthen their existing co-operation for the promotion of Pfizer's Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for active immunisation of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia. 

David Simmons, president and general manager, emerging markets and established products of Pfizer, said: "Our intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of our commitment to expand our presence in China in collaboration with the local industry." 

Shanghai Pharmaceutical has been one of Pfizer's major partners in China for years and is its largest distribution customer in the market.

21st April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics